Refining the provider payment system of India's government-funded health insurance programme: an econometric analysis.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
19 10 2023
Historique:
medline: 23 10 2023
pubmed: 20 10 2023
entrez: 19 10 2023
Statut: epublish

Résumé

Reimbursement rates in national health insurance schemes are frequently weighted to account for differences in the costs of service provision. To determine weights for a differential case-based payment system under India's publicly financed national health insurance scheme, the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), by exploring and quantifying the influence of supply-side factors on the costs of inpatient admissions and surgical procedures. Exploratory analysis using regression-based cost function on data from a multisite health facility costing study-the Cost of Health Services in India (CHSI) Study. The CHSI Study sample included 11 public sector tertiary care hospitals, 27 public sector district hospitals providing secondary care and 16 private hospitals, from 11 Indian states. 521 sites from 57 healthcare facilities in 11 states of India. Medical and surgical packages of PM-JAY. The cost per bed-day and cost per surgical procedure were regressed against a range of factors to be considered as weights including hospital location, presence of a teaching function and ownership. In addition, capacity utilisation, number of beds, specialist mix, state gross domestic product, State Health Index ranking and volume of patients across the sample were included as variables in the models. Given the skewed data, cost variables were log-transformed for some models. The estimated mean costs per inpatient bed-day and per procedure were 2307 and 10 686 Indian rupees, respectively. Teaching status, annual hospitalisation, bed size, location of hospital and average length of hospitalisation significantly determine the inpatient bed-day cost, while location of hospital and teaching status determine the procedure costs. Cost per bed-day of teaching hospitals was 38-143.4% higher than in non-teaching hospitals. Similarly, cost per bed-day was 1.3-89.7% higher in tier 1 cities, and 19.5-77.3% higher in tier 2 cities relative to tier 3 cities, respectively. Finally, cost per surgical procedure was higher by 10.6-144.6% in teaching hospitals than non-teaching hospitals; 12.9-171.7% higher in tier 1 cities; and 33.4-140.9% higher in tier 2 cities compared with tier 3 cities, respectively. Our study findings support and validate the recently introduced differential provider payment system under the PM-JAY. While our results are indicative of heterogeneity in hospital costs, other considerations of how these weights will affect coverage, quality, cost containment, as well as create incentives and disincentives for provider and consumer behaviour, and integrate with existing price mark-ups for other factors, should be considered to determine the future revisions in the differential pricing scheme.

Identifiants

pubmed: 37857541
pii: bmjopen-2023-076155
doi: 10.1136/bmjopen-2023-076155
pmc: PMC10603525
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e076155

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : INV-003239
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Appl Health Econ Health Policy. 2021 May;19(3):353-370
pubmed: 33462775
PLoS One. 2013 Jul 23;8(7):e69728
pubmed: 23936088
J Health Econ. 2006 Nov;25(6):1049-68
pubmed: 16554098
BMJ Open. 2020 Jul 20;10(7):e035170
pubmed: 32690737
BMJ. 2013 Jun 07;346:f3197
pubmed: 23747967
Pharmacoecon Open. 2022 Sep;6(5):745-756
pubmed: 35733075
Cost Eff Resour Alloc. 2018 Mar 19;16:11
pubmed: 29559855
Pharmacoecon Open. 2020 Jun;4(2):249-261
pubmed: 31468323
Health Policy. 2014 Dec;118(3):341-53
pubmed: 25082465
Cost Eff Resour Alloc. 2003 Feb 26;1(1):3
pubmed: 12773218
Soc Work Public Health. 2012;27(5):482-506
pubmed: 22873937
Eur J Health Econ. 2015 Jan;16(1):35-45
pubmed: 24310509
PLoS One. 2018 Apr 2;13(4):e0195179
pubmed: 29608610
Eur J Health Econ. 2018 Apr;19(3):385-408
pubmed: 28439750
PLoS One. 2020 May 13;15(5):e0232873
pubmed: 32401763
Soc Sci Med. 2002 Sep;55(6):895-906
pubmed: 12220092
Appl Health Econ Health Policy. 2020 Oct;18(5):699-711
pubmed: 32170666
Eur J Public Health. 2014 Dec;24(6):1023-8
pubmed: 24627542
Soc Sci Med. 2004 Jul;59(1):199-208
pubmed: 15087154
BMC Health Serv Res. 2022 Nov 14;22(1):1343
pubmed: 36376868
Indian J Med Res. 2017 Sep;146(3):354-361
pubmed: 29355142
PLoS One. 2016 Aug 18;11(8):e0160986
pubmed: 27536781
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794591

Auteurs

Shankar Prinja (S)

Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India shankarprinja@gmail.com.

Pankaj Bahuguna (P)

Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Health Economics and Health Technology Assessment (HEHTA), University of Glasgow, Glasgow, UK.

Maninder Pal Singh (MP)

Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK.

Lorna Guinness (L)

Centre for Global Development, London, UK.

Aarti Goyal (A)

Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Vipul Aggarwal (V)

Government of India, National Health Authority, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH